Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries.
Universal or targeted postarrival screening for latent TB infection (LTBI) has been suggested as a method to accelerate the decline of TB (4); however, domestic LTBI programs exhibit suboptimal performance (5), are resource intensive (6), and may not be cost-effective (7). One major reason for the reduced effectiveness of postarrival LTBI screening programs is the substantial attrition in the LTBI cascade of care. More than half of patients do not reach the point of initiating treatment, which results in fewer than one fifth completing treatment (5).
Currently, most immigrant-receiving, low-incidence countries employ mandatory preimmigration medical exams (8). As part of these medical exams, a chest radiograph and medical evaluation are performed to detect TB disease before arrival or identify those who may be at increased risk for TB disease in the future; these costs are borne by the patient within their country of origin. Only a select few countries employ some form of mandated LTBI screening (8), and data are scarce on the yield of such programs.
A report sponsored by the US Centers for Disease Control and Prevention (Atlanta, GA, USA) suggested mandatory LTBI screening and treatment as part of routine preimmigration medical exams (9); however, this strategy was viewed as inequitable and unjustly coercive (10) and has never been employed. Alternatively, mandating and fully sponsoring only LTBI screening as a formal part of the immigration process would avoid such ethics quandaries and could substantially reduce postarrival TB incidence. Preimmigration screening coupled with postarrival follow-up could improve the yield of LTBI screening programs >2-fold (5), because all case-patients reporting postarrival would already have completed LTBI screening.
We evaluated the cost-effectiveness of mandating and fully sponsoring LTBI screening in prospective migrants as part of routine preimmigration medical exams, coupled with passive postarrival follow-up and treatment. We evaluated 6 strategies among migrants from 4 different TB incidence groups to determine the optimal strategy in each group for this intervention.
We chose discrete event simulation for this model because of its flexibility in varying transition times between health states in a single simulation, ability to simulate simultaneous events, and capability to model several different patient covariates. These advantages make it preferable to traditional Markov models and enable the creation of a highly representative cohort in a single simulation (11). We modeled new migrants, which in this evaluation refers specifically to persons who have been granted permanent resident status but have not yet become citizens of the countries they reside in. Of interest were migrants from countries belonging to 4 distinct TB incidence categories: low, <30 cases/100,000 persons/year; moderate, [greater than or equal to] 30 and <100 cases/100,000 persons/year; high, [greater than or equal to] 100 and <200 cases/100,000 persons/year; and very high, [greater than or equal to] 200 cases/100,000 persons/year.
We further defined the 4 populations of interest by 4 covariates: patient age, bacillus Calmette-Guerin (BCG) vaccination status, chest radiograph results, and LTBI prevalence. Patient age was defined based on an age distribution of a reference cohort of permanent residents to Canada in 2014 (12). BCG vaccination was determined through presence of a universal BCG vaccination policy in each country of origin and adjusted by 36-year average BCG vaccine uptake (13-15). For chest radiograph, a reference cohort of permanent residents who came to Ontario during 2002-2011 was used to identify prevalence of abnormal chest radiograph results (15). LTBI prevalence was calibrated in each population using 2-year TB incidence in permanent resident cohorts to Ontario during 2002-2011 (15) and age-adjusted using the results of a meta-analysis of test-positive rates (16).
We estimated LTBI prevalence using several assumptions. First, we assumed that 85% of incident TB resulted from reactivation of LTBI (17); second, that TB reactivation did not change over time post arrival (18); and last, that LTBI prevalence approximately matched reported rates of interferon-gamma release assay (IGRA) positivity in persons from each of the 4 TB incidence categories (16). In sum, an LTBI reactivation rate of 1.1 cases/1,000 person-years approximated literature values and yielded reasonable estimates of LTBI prevalence (17).
The model evaluates implementation of the intervention: preimmigration LTBI screening coupled with postarrival follow-up and treatment. The base case in this model was considered to be preimmigration TB screening without any evaluation for LTBI before or after arrival but with routine postarrival follow-up for those flagged through TB screening. We calibrated baseline TB incidence estimates and rates of postarrival follow-up to TB incidence data in permanent resident cohorts to Ontario during 2002-2011 (15). We considered 3 preimmigration LTBI screening options and 2 postarrival LTBI treatment options, for a total of 6 unique strategies to compare with the base case (Table 1).
We screened migrants with a tuberculin skin test (TST), IGRA, or sequential screening, in which persons testing positive by TST were given a confirmatory IGRA. We defined a positive TST result as an induration measuring [greater than or equal to]10 mm and a positive IGRA result using manufacturer's recommendations, with IGRA performance being a composite measure of results from commercially available products (19-21). Although preimmigration testing was mandated, postarrival follow-up and treatment was not mandated and instead assumed to be passive, following published rates of postarrival follow-up in several countries (22). That is, in migrants who tested positive for LTBI, it was recommended that they attend a clinic for treatment postarrival, but no system was in place to enforce this. Those who reported for care postarrival would be treated with 9 months of isoniazid or 4 months of rifampin.
The model took a healthcare system perspective for the fully sponsored and mandated preimmigration LTBI screening: all LTBI screening costs preimmigration, along with typical postarrival costs, were the responsibility of the receiving country's healthcare system. We used a 3% annual discount rate for costs and outcomes (23) and a 25-year time horizon from arrival. The main outcomes of the model were quality-adjusted life-years (QALYs), number of TB cases, and costs per 1,000 permanent residents from each of the 4 populations analyzed. These data were used to calculate the cost-effectiveness ratio, a measure that indicates the cost per additional QALY gained by an intervention strategy compared with the base case (Appendix, https://wwwnc.cdc.gov/EID/article/25/4/17-1630-App1.pdf).
A simplified model structure is displayed in Figure 1. In the intervention, migrants were given an LTBI diagnostic test along with the rest of their medical exam; those who tested positive were referred for postarrival follow-up. Those who complied with postarrival follow-up were recommended for LTBI therapy. After initiating treatment, they either completed treatment in full, partially completed treatment, or ceased due to an adverse event that may result in death. After treatment, results for all patients were simulated to the 25-year time horizon, with annual risks of TB reactivation and death.
We made the following assumptions in the model. Those with previous TB or an abnormal chest radiograph result identified during the preimmigration medical exam were also referred for postarrival follow-up. With the intervention, all those who began screening completed it, eliminating dropout during this stage of the LTBI cascade of care. Drug-resistant TB and self-cure of LTBI were not modeled. It was assumed that all those who tested positive were offered LTBI treatment to limit extrapolation of care provider decisions. All reactivation TB cases had a 17.6% chance of causing a secondary case; further transmission was not modeled (Appendix). Modeling was completed in Simio version 8.146.14121 (Simio LLC, https://www.simio.com).
We derived model estimates from the literature or expert opinion (Table 2). A meta-analysis provided evidence for domestic LTBI program performance (5), therapy efficacy was derived from the literature (24,27,28), and adverse events were imputed from several randomized controlled trials reported in previous analysis (24,25). Diagnostic performance of LTBI screening tests was derived from systematic reviews and modeled to be the same in each country (19-21). Adherence with postarrival follow-up was estimated by reanalysis of reported data (22) (Appendix Figure 1). Death from tuberculosis (5), probability of TB therapy extension (30), and relapse rate (51) were derived from Canada sources. Life tables for Canada estimated background mortality (32).
We derived all costs from Canada sources and assumed that the costs of screening abroad were equal to screening costs in Canada. We derived costs for LTBI treatment and screening, including drugs, screening tests, routine monitoring, and clinician time, from the British Columbia Centre for Disease Control. Adverse event costs, including hospitalization rates and time, and the cost of TB disease were as reported in the literature (30,33,34). We inflated all costs to 2016 Canadian dollars using consumer price indices (35) (Table 3).
We derived health utility data from a study (38) in Canada of migrants who reported for postarrival follow-up. We based adjustments due to adverse events or hospitalization on previous studies (30,33).
We performed a probabilistic sensitivity analysis (PSA) to capture uncertainty of model estimates using an outer sample size of 1,000 and inner sample size of 50,000 (Tables 2, 3). To guide policymakers, we created cost-effectiveness acceptability curves (CEAC) to determine the probability that the most cost-effective intervention strategy in deterministic analysis would fall below various willingness-topay (WTP) thresholds. Exploratory sensitivity analysis and additional probabilistic sensitivity analyses are included in the Appendix.
Among migrants from moderate- to very high-incidence countries, IGRA screening coupled with postarrival rifampin treatment was the optimal intervention strategy in deterministic analysis. Sequential screening coupled with postarrival rifampin treatment was the optimal intervention strategy among migrants from low-incidence countries. Intervention strategies involving TST identified the most migrants for postarrival follow-up, whereas strategies involving sequential screening identified the fewest. Intervention strategies involving rifampin resulted in the fewest TB cases (46% reduction compared with the base case) (Table 4).
For migrants from low-incidence countries, screening with TST alone resulted in a net loss in population QALYs because of poor specificity of the TST. Sequential screening, the most specific screening method, coupled with postarrival rifampin treatment yielded the lowest cost per QALY gained at $191,889. IGRA screening, the most sensitive screening method, coupled with rifampin treatment resulted in the fewest TB cases (46.2% reduction) but had a higher cost per QALY gained ($373,773) because of its lower specificity compared with that of sequential screening.
For migrants from moderate-incidence countries, the optimal intervention strategy was IGRA screening coupled with postarrival rifampin treatment for those from moderate-incidence countries with a cost per QALY gained of $43,343. Sequential screening coupled with postarrival rifampin treatment was cheaper overall but had a cost per QALY gained of $47,561.
Among migrants from high-incidence countries, IGRA screening coupled with postarrival rifampin treatment was the optimal intervention strategy, at a cost per QALY gained of $26,350. Sequential screening coupled with rifampin treatment was less expensive, but also less efficient, with a cost per QALY gained of $29,997.
Very High-Incidence Countries
Among migrants from very high-incidence countries, IGRA screening coupled with postarrival rifampin treatment had a cost per QALY gained of $16,291 compared with the base case. Sequential screening with rifampin treatment again was slightly cheaper, resulting in a cost per QALY gained of $20,165.
Among migrants from low-incidence countries, sequential screening coupled with postarrival rifampin treatment was the most cost-effective option in deterministic analysis. In PSA, this intervention had a probability of cost-effectiveness of 49.1% at a WTP threshold of $50,000/QALY and 50.7% at a WTP threshold of $100,000/QALY. This probability did not substantially increase past these thresholds, however, resulting in a probability of cost-effectiveness of 52% at a WTP threshold of $200,000/QALY (Figure 2, panel A).
Among migrants from moderate-, high-, and very high-incidence countries, IGRA screening coupled with postarrival rifampin treatment was the most cost-effective option in deterministic analysis. This intervention strategy at WTP thresholds of $50,000/QALY gained had probabilities of cost-effectiveness of 57.5% among migrants from moderate-incidence countries (Figure 2, panel B), 68.2% among migrants from high-incidence countries (Figure 2, panel C), and of 73.2% among migrants from very high-incidence countries (Figure 2, panel D). At a WTP threshold of $100,000/QALY gained probabilities of cost-effectiveness were 59.8% among migrants from moderate-incidence countries, 70.6% among migrants from high-incidence countries, and 75.2% among migrants from very high-incidence countries.
The intervention of preimmigration LTBI screening followed by postarrival treatment among new migrants from countries with a TB incidence [greater than or equal to] 30 cases/100,000 persons appears to be an effective method for reducing TB incidence post-arrival. The use of IGRA screening coupled with postarrival rifampin treatment provided the lowest cost-effectiveness ratio in migrants from these countries. This intervention strategy reduced TB incidence by >45% and yielded costs <$50,000/QALY gained.
Because prevalence of LTBI was low among migrants from countries with a TB incidence <30 cases/100,000 persons and specificities of LTBI diagnostic tests are imperfect, this intervention may result in a high number of uninfected persons receiving treatment unnecessarily. This finding suggests that with some strategies, the QALYs lost due to treatment side effects among those with false-positive diagnostic results may be greater than the QALYs gained by averted TB in those with true-positive diagnostic results. If screening and treatment must be performed in these low LTBI prevalence populations, more specific screening methods (i.e., sequential screening) are preferred to avoid inappropriate treatment.
Probabilistic sensitivity analysis suggests a certain degree of uncertainty in results. The behavior of CEACs as WTP thresholds increase suggests that the intervention offers small increases in population QALYs or large increases in cost in many replications. It is important to understand how well the model parameters represent the local setting when using the results of this analysis to inform evidence-based policy. These results suggest that intervention offers domestic benefits to the receiving country, but several factors need to be carefully examined. IGRA use in high-resource settings suffers from variability, in part related to several operational issues (39), and TST variability remains an issue (40). For both types of test, variability may be exacerbated in low-resource settings where LTBI prevalence rates are likely to be higher. In this model, we did not consider the costs of program initiation and maintenance; although they are outside the scope of this analysis, these costs merit careful evaluation when seeking to implement policy.
This model considered only the costs of persons who became permanent residents. The data from Canada indicated that [approximately equal to] 50%-60% of those who begin the process of becoming a permanent resident successfully complete it (3,15). For migrants from very high-incidence countries, assuming only half of migrants receiving preimmigration screening became permanent residents, the cost-effectiveness ratio increased 60% to [approximately equal to] $26,000 when the intervention strategy was IGRA coupled with rifampin. Another consideration is the feasibility of the intervention. In a country like Canada, 2%-3% of new permanent residents are requested to follow up postarrival based on preimmigration medical exams (3,15). If the country implemented preimmigration IGRA screening for migrants from moderate-to very high-incidence countries, 17.6% would be requested to follow up postarrival (3,15). However, coupling IGRA with postarrival rifampin treatment could prevent 3.9% of all TB cases in Canada in the first year (3,12,15). Applied to new permanent residents to Canada in 2014, this process would increase the number requested to follow up postarrival from 6,100 to 45,800 but would result in the prevention of 61 TB cases in the first year (1 case prevented/ 651 additional postarrival referrals). If this process were then consistently implemented in successive cohorts in the future, it could annually prevent [approximately equal to] 400 TB cases.
Regardless of how preimmigration LTBI screening is implemented, investment in LTBI infrastructure in high TB incidence settings will be essential for global TB elimination. Evidence suggests that introduction of routine preimmigration TB screening in many high-income, low-incidence countries has played a role in improving infrastructure for TB programs in low-resource areas (41). Further introducing LTBI screening as part of these routine medical exams may have similar impact.
The cost-effectiveness of preimmigration LTBI screening and postarrival treatment has not been evaluated since 2003. Previously, Schwartzman and Menzies (42) examined the idea of preimmigration TST screening in addition to standard preimmigration chest radiograph coupled with postarrival isoniazid treatment. They found the cost per TB case prevented was approximately Can $94,500. In our study, using this intervention strategy in very high incidence countries resulted in a cost per TB case prevented of approximately Can $83,000. Schwartzman et al. (43) later investigated the cost associated with performing a TST in all new legal immigrants from Mexico, a low-incidence country, and coupling it with postarrival isoniazid treatment. This resulted in a cost per TB case prevented of $1.2 million (2016 Can $). Using this same intervention strategy in our study resulted in a cost per TB case prevented of $1.1 million (2016 Can $). By evaluating new strategies applied to a variety of TB incidence settings, our study represents a much-needed update to the literature.
Our analysis has several strengths. Use of discrete event simulation enabled realistic modeling of time spent in various health states, which is difficult to implement in Markov models. This type of model also allowed age-representative modeling of new migrants for application of age-adjusted LTBI prevalence. The source of most of the cost data was the British Columbia Center for Disease Control, which handles most TB cases in the province of British Columbia. This analysis estimated LTBI prevalence and abnormal chest radiograph prevalence using several years of immigration and TB data from Ontario. The data are likely to be generalizable, because Ontario accepts 40% of new permanent residents (12) and the data fit well with reported LTBI prevalence estimates (16), suggesting these parameters are reflective of long-term TB trends.
In this study, we assumed that all migrants were recommended postarrival LTBI treatment when they had a positive LTBI diagnostic test, which is not necessarily true; for some persons, the risk for serious adverse events may outweigh the benefit of treatment. Social factors and concurrent conditions may increase the risk for reactivation of LTBI. We have shown that the benefits of rifampin treatment for migrants from moderate- to very high-incidence countries who test positive by IGRA preimmigration outweigh the potential risks of adverse events. However, in practice, individual adverse-event risk is considered, and treatment may not be offered to all migrants. Further research designed to identify the specific populations who should be offered treatment would help inform future analyses.
We derived the reactivation rate of LTBI from the literature, but because many of those studies were based on TB incidence in those who were positive by TST, it is possible that the predictive value of the TST caused underestimation of true reactivation rates. Our analysis did not consider 3 months of once-weekly isoniazid and rifapentine as an LTBI treatment modality because it was not universally available. Literature data, however, suggest this modality may yield similar results to rifampin treatment (44).
Our analysis used a healthcare system perspective, which does not consider costs incurred by persons experiencing the intervention (45). It is possible that consideration of costs and benefits from a societal perspective would change the results of this analysis; however, it is also likely that this difference would strengthen the preference for screening with IGRA, which requires only 1 visit, instead of TST, which requires 2, due to reduced absenteeism associated with IGRA testing. Costs per QALY gained may increase for all strategies if the time costs for migrants to follow up for LTBI treatment were considered. Finally, we assumed that TB reactivation was constant, which, while demonstrated previously (18), contradicts the common paradigm of decreasing risk over time (46). Where possible, we performed sensitivity analyses to view the effects our limitations may have on our results to better inform decision makers.
In conclusion, preimmigration IGRA screening coupled with postarrival rifampin treatment among migrants from countries with moderate to very high incidence of TB resulted in the lowest cost-effectiveness ratios. This evidence can be used to support policy decisions surrounding preimmigration LTBI screening in high-income, immigrant-receiving countries, when coupled with evaluations on program implementation, acceptability, and sustainability. Next steps in research should be to identify subgroups at highest risk for progression to TB disease to limit individual risk associated with LTBI treatment and improve the likelihood of feasibility and sustainability.
EID Podcast: Extensively Drug-Resistant TB
Tuberculosis (TB) remains a major cause of illness and death in the 21st century. There were an estimated 9.6 million incident cases worldwide in 2014. In addition, an estimated 3.3% of new cases and 20% of retreatment cases are multidrug-resistant TB (MDR TB), which is defined as TB resistant to at least rifampin and isoniazid, the 2 most powerful first-line drugs. This resistance threatens global TB control efforts. MDR TB patients need access to treatment, require longer treatment with toxic medications, and have a lower probability of cure. Visit our website to listen: https://www2c.cdc.gov/podcasts/player.asp?f=8644444
The authors would like to thank Shannon Kopp and John Danas for their help with costing and Simio LLC (http://www.simio.com) for allowing use of their software and replication runner.
J.C.J. and M.S. have received funding from the Michael Smith Foundation for Health Research. M.S. also received salary support from the Canadian Institutes of Health Research.
J.R.C., J.C.J., and F.M. were involved in development of the study objective and design. J.R.C. performed data collection, created the model, performed data analysis and interpretation, and drafted the manuscript. J.C.J. provided expert input on the data informing the model, data interpretation, and performed manuscript editing. M.S. reviewed the model for errors, provided expert input for data analysis, and edited the manuscript. V.J.C. provided expert input on the data informing the model and edited the manuscript. R.K.E. provided expert input on the data interpretation and edited the manuscript. F.M. reviewed the model inputs collected and the data analysis, provided expert input for data interpretation, and edited the manuscript. All authors approved the study objective, design, and final manuscript.
Dr. Campbell received his PhD from the University of British Columbia in Vancouver and is currently a postdoctoral fellow at McGill University in Montreal, Quebec, Canada. His primary research interests include health economics, evidence-based public health policy, and infectious disease.
(1.) World Health Organization. Framework towards tuberculosis elimination in low-incidence countries. Geneva: The Organization; 2014 [cited 2018 Mar 7]. http://www.who.int/tb/publications/ elimination_framework/en/
(2.) Pareek M, Greenaway C, Noori T, Munoz J, Zenner D. The impact of migration on tuberculosis epidemiology and control in high-income countries: a review. BMC Med. 2016;14:48. http://dx.doi.org/10.1186/s12916-016-0595-5
(3.) Public Health Agency of Canada. Canadian tuberculosis standards, 7th ed. Ottawa (ON): Government of Canada; 2014 [cited 2018 Mar 7]. https://www.canada.ca/en/public-health/services/infectiousdiseases/canadian-tuberculosis-standards-7th- edition.html
(4.) Taylor Z, Nolan CM, Blumberg HM; American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep. 2005;54(RR-12):1-81.
(5.) Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16:1269-78. http://dx.doi.org/10.1016/S1473-3099(16) 30216-X
(6.) Campbell J, Marra F, Cook V, Johnston J. Screening immigrants for latent tuberculosis: do we have the resources? CMAJ. 2014;186:246-7. http://dx.doi.org/10.1503/cmaj.131025
(7.) Campbell JR, Sasitharan T, Marra F. A systematic review of studies evaluating the cost utility of screening high-risk populations for latent tuberculosis infection. Appl Health Econ Health Policy. 2015;13:325^0. http://dx.doi.org/10.1007/s40258-015-0183-4
(8.) Pareek M, Baussano I, Abubakar I, Dye C, Lalvani A. Evaluation of immigrant tuberculosis screening in industrialized countries. Emerg Infect Dis. 2012;18:1422-9. http://dx.doi.org/10.3201/ eid1809.120128
(9.) Institute of Medicine (US) Committee on the Elimination of Tuberculosis in the United States. Ending neglect: the elimination of tuberculosis in the United States. Geiter L, editor. Washington (DC): National Academies Press; 2000.
(10.) Coker R, van Weezenbeek KL. Mandatory screening and treatment of immigrants for latent tuberculosis in the USA: just restraint? Lancet Infect Dis. 2001;1:270-6. http://dx.doi.org/10.1016/ S1473-3099(01)00122-0
(11.) Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, Moller J; ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--4. Value Health. 2012;15:821-7. http://dx.doi.org/10.1016/). jval.2012.04.013
(12.) Statistics Canada. Report on the demographic situation in Canada: permanent and temporary immigration to Canada from 2012 to 2014. Ottawa (ON): Government of Canada; 2016 [cited 2018 Mar 7]. http://www.statcan.gc.ca/pub/91-209-x/2016001/article/ 14615-eng.htm
(13.) Badar S, Araujo T, Zwerling A, Pai M. BCG world atlas. 2nd edition. 2017 [cited 2018 Mar 7]. http://www.bcgatlas.org/index.php
(14.) World Health Organization; UNICEF. WHO-UNICEF estimates of BCG coverage. Geneva: World Health Organization; 2017 [cited 2018 Mar 7]. http://apps.who.int/immunization_monitoring/ globalsummary/timeseries/tswucoveragebcg.html
(15.) Khan K, Hirji MM, Miniota J, Hu W, Wang J, Gardam M, et al. Domestic impact of tuberculosis screening among new immigrants to Ontario, Canada. CMAJ. 2015;187:E473-81. http://dx.doi.org/ 10.1503/cmaj.150011
(16.) Campbell JR, Chen W, Johnston J, Cook V, Elwood K, Krot J, et al. Latent tuberculosis infection screening in immigrants to low-incidence countries: a meta-analysis. Mol Diagn Ther. 2015;19:107-17. http://dx.doi.org/10.1007/s40291-015-0135-6
(17.) Shea KM, Kammerer JS, Winston CA, Navin TR, Horsburgh CR Jr. Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol. 2014;179:216-25. http://dx.doi.org/10.1093/aje/ kwt246
(18.) Walter ND, Painter J, Parker M, Lowenthal P, Flood J, Fu Y, et al.; Tuberculosis Epidemiologic Studies Consortium. Persistent latent tuberculosis reactivation risk in United States immigrants. Am J Respir Crit Care Med. 2014;189:88-95.
(19.) Campbell JR, Krot J, Elwood K, Cook V, Marra F. A systematic review on TST and IGRA tests used for diagnosis of LTBI in immigrants. Mol Diagn Ther. 2015;19:9-24. http://dx.doi.org/ 10.1007/s40291-014-0125-0
(20.) Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146:340-54. http://dx.doi.org/10.7326/0003-4819-146-5-200703060-00006
(21.) Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149:177-84. http://dx.doi.org/10.7326/ 0003-4819-149-3-200808050-00241
(22.) Chan IHY, Kaushik N, Dobler CC. Post-migration follow-up of migrants identified to be at increased risk of developing tuberculosis at pre-migration screening: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17:770-9. http://dx.doi.org/ 10.1016/S1473-3099(17)30194-9
(23.) Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses. JAMA. 2016;316:1093103. http://dx.doi.org/10.1001/jama.2016.12195
(24.) Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379:440-53. http://dx.doi.org/10.1056/NEJMoa1714283
(25.) Campbell JR, Johnston JC, Sadatsafavi M, Cook VJ, Elwood RK, Marra F. Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to Canada. PLoS One. 2017;12:e0186778. http://dx.doi.org/10.1371/journal.pone.0186778
(26.) Salpeter SR. Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis. West J Med. 1993;159:560-4.
(27.) International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60:555-64.
(28.) Reichman LB, Lardizabal A, Hayden CH. Considering the role of four months of rifampin in the treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2004;170:832-5. http://dx.doi.org/10.1164/rccm.200405-584PP
(29.) Aldridge RW, Zenner D, White PJ, Williamson EJ, Muzyamba MC, Dhavan P, et al. Tuberculosis in migrants moving from high-incidence to low-incidence countries: a population-based cohort study of 519,955 migrants screened before entry to England, Wales, and Northern Ireland. Lancet. 2016;388:2510-8. http://dx.doi.org/10.1016/S0140-6736(16)31008-X
(30.) Holland DP, Sanders GD, Hamilton CD, Stout JE. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med. 2009;179:1055-60. http://dx.doi.org/10.1164/rccm.200901-0153OC
(31.) Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, et al.; Tuberculosis Trials Consortium. Recurrent tuberculosis in the United States and Canada. Am J Respir Crit Care Med. 2004;170:1360-6. http://dx.doi.org/10.1164/ rccm.200408-1081OC
(32.) Statistics Canada. Life tables, Canada, provinces, and territories. 2016 [cited 2018 Mar 7]. http://www5.statcan.gc.ca/olc-cel/ olc.action?objId=84-537-X&objType=2&lang=en&limit=0
(33.) Marra F, Marra CA, Sadatsafavi M, Moran-Mendoza O, Cook V, Elwood RK, et al. Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts. Int J Tuberc Lung Dis. 2008;12:1414-24.
(34.) Menzies D, Lewis M, Oxlade O. Costs for tuberculosis care in Canada. Can J Public Health. 2008;99:391-6.
(35.) Statistics Canada. Consumer price index, annual average, not seasonally adjusted. 2019 [cited 2018 Mar 7]._ https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1810000501
(36.) Tan MC, Marra CA, Sadatsafavi M, Marra F, Moran-Mendoza O, Moadebi S, et al. Cost-effectiveness of LTBI treatment for TB contacts in British Columbia. Value Health. 2008;11:842-52. http://dx.doi.org/10.1111/j.1524-4733.2008.00334.x
(37.) Fassbender K, Fainsinger RL, Carson M, Finegan BA. Cost trajectories at the end of life: the Canadian experience. J Pain Symptom Manage. 2009;38:75-80. http://dx.doi.org/10.1016/ j.jpainsymman.2009.04.007
(38.) Bauer M, Ahmed S, Benedetti A, Greenaway C, Lalli M, Leavens A, et al. The impact of tuberculosis on health utility: a longitudinal cohort study. Qual Life Res. 2015;24:1337-49. http://dx.doi.org/10.1007/s11136-014-0858-6
(39.) Tagmouti S, Slater M, Benedetti A, Kik SV, Banaei N, Cattamanchi A, et al. Reproducibility of interferon gamma (IFN-y) release assays. a systematic review. Ann Am Thorac Soc. 2014; 11:1267-76. http://dx.doi.org/10.1513/AnnalsATS.201405-188OC
(40.) Pouchot J, Grasland A, Collet C, Coste J, Esdaile JM, Vinceneux P. Reliability of tuberculin skin test measurement. Ann Intern Med. 1997;126:210-4. http://dx.doi.org/10.7326/ 0003-4819-126-3-199702010-00005
(41.) Douglas P, Posey DL, Zenner D, Robson J, Abubakar I, Giovinazzo G. Capacity strengthening through pre-migration tuberculosis screening programmes: IRHWG experiences. Int J Tuberc Lung Dis. 2017;21:737-45. http://dx.doi.org/10.5588/ijtld.17.0019
(42.) Schwartzman K, Menzies D. Tuberculosis screening of immigrants to low-prevalence countries: a cost-effectiveness analysis. Am J Respir Crit Care Med. 2000;161:780-9. http://dx.doi.org/10.1164/ ajrccm.161.3.9902005
(43.) Schwartzman K, Oxlade O, Barr RG, Grimard F, Acosta I, Baez J, et al. Domestic returns from investment in the control of tuberculosis in other countries. N Engl J Med. 2005;353:1008-20. http://dx.doi.org/10.1056/NEJMsa043194
(44.) Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al.; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155-66. http://dx.doi.org/10.1056/NEJMoa1104875
(45.) Byford S, Raftery J. Perspectives in economic evaluation. BMJ. 1998;316:1529-30. http://dx.doi.org/10.1136/bmj.316.7143.1529
(46.) Comstock GW. Frost revisited: the modern epidemiology of tuberculosis. Am J Epidemiol. 1975;101:363-82. http://dx.doi.org/10.1093/oxfordjournals.aje.a112105
Address for correspondence: Fawziah Marra, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada; email: firstname.lastname@example.org
Author affiliations: University of British Columbia, Vancouver, British Columbia, Canada (J.R. Campbell, J.C. Johnston, V.J. Cook, M. Sadatsafavi, R.K. Elwood, F. Marra); British Columbia Centre for Disease Control, Vancouver (J.C. Johnston, V.J. Cook, R.K. Elwood)
Caption: Figure 1. Flow structure of model used for cost-effectiveness analysis of screening and interventions of migrants for TB and LTBI. LTBI, latent tuberculosis infection; TB, tuberculosis.
Caption: Figure 2. Cost-effectiveness acceptability curves of the base case of no intervention compared with intervention strategies in evaluation of screening and treatment of latent tuberculosis infection in immigrants. The graphs demonstrate the probability that an option is more cost-effective at various willingness-to-pay thresholds per quality adjusted life year gained. A) Comparison of the base case with the intervention strategy of preimmigration SEQ screening coupled with postarrival RIF treatment among migrants from low- incidence countries. B) Comparison of the base case with the intervention strategy of preimmigration IGRA screening coupled with postarrival rifampin treatment among migrants from moderate-incidence countries. C) Comparison of the base case with the intervention strategy of preimmigration IGRA screening coupled with postarrival RIF treatment among migrants from high-incidence countries. D) Comparison of the base case with the intervention strategy of preimmigration IGRA screening coupled with postarrival RIF treatment among migrants from very high-incidence countries. IGRA, interferon-gamma release assay; RIF, rifampin; SEQ, sequential.
Table 1. Intervention strategies for screening and treatment of latent TB infection in immigrants * Intervention Preimmigration Postarrival if test is strategy positive Base case TB screening as part of Routine follow-up of routine preimmigration those with abnormal chest medical exams, consisting radiograph results or of a chest radiograph, previous TB. medical history, and symptom screen. If diagnosed with TB, treatment must be completed before immiqratinq. TST/INH In addition to the base Recommendation for case, a TST is performed follow-up; if patient at the time of the reports for follow-up, 9- medical exam. If the month course of INH. result is positive (induration [greater than or equal to] 10 mm) referral is made for follow-up postarrival. If the TST result is negative, no further action is taken. TST/RIF Same as above. Recommendation for follow-up; at follow-up, 4-month course of RIF. IGRA/INH In addition to the base Recommendation for case, an IGRA is placed follow-up; if patient at the time of the reports for follow-up, 9- medical exam. If the month course of INH. result is positive (as defined by the manufacturer) referral is made for follow-up postarrival. If the IGRA result is negative, no further action is taken. If the IGRA result is indeterminate, a second is performed; a second consecutive indeterminate is treated as a negative. IGRA/RIF Same as above. Recommendation for follow-up; if patient reports for follow-up, 4- month course of RIF. SEQ/INH In addition to the base Recommendation for case, a TST is placed at follow-up; at follow-up, the time of the medical 9-month course of INH. exam. If the result is positive (as defined by an induration [greater than or equal to] 10 mm) a second test is performed with an IGRA. If the subsequent IGRA result is positive (as defined by the manufacturer) referral is made for follow-up postarrival. If the initial TST is negative or if the subsequent IGRA is negative, no further action is taken. If the IGRA result is indeterminate, a second is performed; a second consecutive indeterminate is treated as a negative. SEQ/RIF Same as above. Recommendation for follow-up; at follow-up, 4-month course of RIF. * No intervention required for migrants with negative results of base case screening. IGRA, interferon-gamma release assay; INH, isoniazid; RIF, rifampin; SEQ, sequential screening; TB, tuberculosis TST, tuberculin skin test. Table 2. Model parameter estimates and values used for sensitivity analyses of intervention strategies for screening and treatment of latent TB infection in immigrants * Parameter Estimate Range evaluated in PSA Screening parameters TST sensitivity 0.782 0.69-0.87 TST specificity, no BCG 0.974 0.963-0.982 TST specificity, BCG 0.602 0.561-0.642 IGRA sensitivity 0.889 0.688-0.993 IGRA specificity 0.957 0.946-0.968 IGRA indeterminat 0.06 0.05-0.07 ([dagger]) Complete TST 1 Fixed ([double dagger]) Complete medical 1 Fixed evaluations ([section]) Population characteristics ([paragraph]) LTBI prevalence Very high incidence 0.3162 0.2686-0.3880 High incidence 0.2016 0.1706-0.2464 Moderate incidence 0.0902 0.0763-0.1102 Low incidence 0.0159 0.0135-0.0195 Abnormal chest radiograph results or previous TB Very high incidence 0.039 Fixed High incidence 0.028 Fixed Moderate incidence 0.029 Fixed Low incidence 0.008 Fixed Adherence to postarrival 0.684 0.646-0.721 follow-up (#) Treatment parameters Initiate ** 0.938 0.907-0.964 Complete, INH 0.616 0.561-0.670 Complete, RIF 0.814 0.745-0.876 Adverse event, INH 0.049 0.044-0.055 Adverse event, RIF 0.021 0.018-0.025 Adverse event hospitalization 0.01 0.0005-0.03 Death, INH 0.00000988 0-0.00002 LTBI risk reduction, INH 0.90 0.78-0.95 LTBI risk reduction, RIF 0.90 0.63-0.97 Partial risk reduction, INH 0.346 0.267-0.490 Partial risk reduction, RIF 0.30 0.17-0.40 Adverse event duration 7 d 0-24 TB parameters Death from TB 0.0476 0.0391-0.0566 Reactivation rate 0.0011 0.0009-0.0013 Abnormal CXR risk change 3.9 3.0-4.9 Extended therapy 0.124 0.029-0.264 Relapse rate 0.0359 0.0197-0.0654 Hospitalization duration 17 d Fixed Model parameters BCG vaccination, 0.605 0.60-0.61 <30 cases BCG vaccination, 0.998 0.997-0.999 [greater than or equal to]30 cases BCG vaccination uptake 0.837 Fixed Discount rate 0.03 Fixed Time horizon 25 y Fixed Parameter PSA distribution Screening parameters TST sensitivity Beta (43,12) TST specificity, no BCG Beta (770,21) TST specificity, BCG Beta (239,158) IGRA sensitivity Beta (8,1) IGRA specificity Beta (900,40) IGRA indeterminat Beta (83,1286) ([dagger]) Complete TST Fixed ([double dagger]) Complete medical Fixed evaluations ([section]) Population characteristics ([paragraph]) LTBI prevalence Very high incidence Varied with reactivation rate High incidence Varied with reactivation rate Moderate incidence Varied with reactivation rate Low incidence Varied with reactivation rate Abnormal chest radiograph results or previous TB Very high incidence Fixed High incidence Fixed Moderate incidence Fixed Low incidence Fixed Adherence to postarrival Beta follow-up (#) (404.50,186.87) Treatment parameters Initiate ** Beta (180.83,11.95) Complete, INH Beta (131.66,82.07) Complete, RIF Beta (76.85,17.56) Adverse event, INH Beta (249,4789) Adverse event, RIF Beta (109,4877) Adverse event hospitalization Beta (1,99) Death, INH Beta (2,202495) LTBI risk reduction, INH Normal (-2.3,0.5) ([dagger][dagger]) LTBI risk reduction, RIF Normal (-2.3,0.8) ([dagger][dagger]) Partial risk reduction, INH Combination of normal distributions ([dagger][dagger]) ([double dagger]) ([double dagger]) Partial risk reduction, RIF Normal (-0.35,0.1) ([dagger][dagger]) Adverse event duration Gamma (0.7,10) TB parameters Death from TB Beta (76,1523) Reactivation rate Beta (90.92,82545.55) Abnormal CXR risk change Normal (1.36,0.15) ([dagger][dagger]) Extended therapy Beta (2.366,16.713) Relapse rate Normal (-3.327,0.365) ([dagger][dagger]) Hospitalization duration Fixed Model parameters BCG vaccination, Beta (45137,29502) <30 cases BCG vaccination, Beta (185381,384) [greater than or equal to]30 cases BCG vaccination uptake Fixed Discount rate Fixed Time horizon Fixed Parameter References Screening parameters TST sensitivity (19) TST specificity, no BCG (20,21) TST specificity, BCG (20,21) IGRA sensitivity (19) IGRA specificity (20,21) IGRA indeterminat (21) ([dagger]) Complete TST ([double dagger]) Complete medical evaluations ([section]) Population characteristics ([paragraph]) LTBI prevalence Very high incidence (12,15-17) High incidence (12,15-17) Moderate incidence (12,15-17) Low incidence (12,15-17) Abnormal chest radiograph results or previous TB Very high incidence (15) High incidence (15) Moderate incidence (15) Low incidence (15) Adherence to postarrival (22) follow-up (#) Treatment parameters Initiate ** (5) Complete, INH (5) Complete, RIF (5) Adverse event, INH (24,25) Adverse event, RIF (24,25) Adverse event hospitalization (25) Death, INH (26) LTBI risk reduction, INH (27) LTBI risk reduction, RIF (28,24) Partial risk reduction, INH Expert opinion, (25) Partial risk reduction, RIF Expert opinion, Adverse event duration (24,28) Expert opinion, (25) TB parameters Death from TB (3) Reactivation rate (15-17) Abnormal CXR risk change (29) Extended therapy Expert opinion, (30) Relapse rate (30) Hospitalization duration Expert opinion, (30) Model parameters BCG vaccination, (12,13) <30 cases BCG vaccination, (12,13) [greater than or equal to]30 cases BCG vaccination uptake (14) Discount rate (23) Time horizon NA * AE, adverse event; BCG, bacillus Calmette-Guerin; IGRA, interferon-gamma release assay; INH, isoniazid; LTBI, latent tuberculosis infection; NA, not available; PSA, probabilistic sensitivity analysis; RIF, rifampin; TST, tuberculin skin test; TB, tuberculosis. ([dagger]) Treated as a negative result if it occurred; was equally likely to occur in those with and without LTBI. ([double dagger]) Without being mandatory, this value is 63.5% (imputed from 43.4% completing screening when 68.4% adhere with a follow-up appointment) (5). ([section]) Without being mandatory, this value is 78% (imputed from 43.7 of 56 individuals completing medical evaluation) (5). ([paragraph]) Very high incidence, [greater than or equal to] 200 cases/100,000; high incidence, [greater than or equal to] 100 and <200 cases/100,000; moderate incidence, [greater than or equal to] 30 and <100 cases/100,000; low incidence, <30 cases/100,000. (#) From a meta-analysis (22); see also Appendix (https://wwwnc.cdc.gov/EID/article/25/4/17-1630-App1.pdf). ** This model assumes all who report postarrival due to a positive preimmigration LTBI diagnostic test are offered treatment. Exploratory analysis adjusts this assumption so that only the number who would complete TST screening begin treatment. ([dagger][dagger]) Results from this distribution are exponentiated. ([double dagger][double dagger]) Formula: 0.33 x (Normal(-1.168,0.228)) + 0.374 x (Normal(-0.381,0.169)) + 0.293 x 1. Table 3. Cost and QALY estimates and values used for sensitivity analysis of intervention strategies for screening and treatment of latent TB infection in immigrants * Parameters Estimate, Range $ evaluated in PSA Costs Full INH treatment 992 804-1,179 Drug costs 181 Nurse and clinician costs 741 Follow-up chest radiograph 42 Routine tests 28 Full RIF treatment 575 464-686 Drug costs 98 Nurse and clinician costs 421 Follow-up chest radiograph 42 Routine tests 14 Partial INH 462 174-804 Partial RIF 319 178-464 Complete TST 31 24-38 TST cost 11 Nurse costs (2 visits) 20 Incomplete TST 21 17-25 IGRA 54 31 -62 Kit and technician cost 47 Nurse costs 7 Chest radiograph 42 32-52 Cost per radiograph 35 Nurse costs 7 TB 20,532 7,141-39,525 LTBI adverse event 732 549-916 Hospitalization 6,641 5,305-9,985 Death 26,933 13,079-40,788 QALYs LTBI 0.81 Healthy 0.81 0.58-0.97 Adverse event disutility 0.2 0.15-0.25 TB 0.69 0.08-0.24 ([dagger]) Hospitalization 0.5 0.28-0.51 ([dagger]) Death 0 Fixed Parameters PSA distribution Costs Full INH treatment Triangular, 804-1,179 Drug costs Nurse and clinician costs Follow-up chest radiograph Routine tests Full RIF treatment Triangular, 464-686 Drug costs Nurse and clinician costs Follow-up chest radiograph Routine tests Partial INH Triangular, 174-804 Partial RIF Triangular, 178-464 Complete TST Triangular, 24-38 TST cost Nurse costs (2 visits) Incomplete TST Triangular, 17-25 IGRA Triangular, 31 -62 Kit and technician cost Nurse costs Chest radiograph Triangular, 32-52 Cost per radiograph Nurse costs TB Gamma (4.1064,5,000) LTBI adverse event Triangular, 549-916 Hospitalization Triangular, 5,305-9,985 Death Triangular, 13,079-40,788 QALYs LTBI Assumed Healthy Beta (7.85,1.84) Adverse event disutility Triangular, [+ or -] 25% TB Beta (9,51) Hospitalization Beta (19.5,30.5) Death Fixed Parameters References Costs Full INH treatment BCCDC, (33,36) Drug costs Nurse and clinician costs Follow-up chest radiograph Routine tests Full RIF treatment BCCDC, (33,36) Drug costs Nurse and clinician costs Follow-up chest radiograph Routine tests Partial INH BCCDC, (33,36) Partial RIF BCCDC, (33,36) Complete TST BCCDC, (33,36) TST cost Nurse costs (2 visits) Incomplete TST BCCDC, (33,36) IGRA BCCDC, (33,36) Kit and technician cost Nurse costs Chest radiograph BCCDC, (33,36) Cost per radiograph Nurse costs TB Expert opinion, (33,34) LTBI adverse event (33) Hospitalization (30) Death (37) QALYs LTBI (38) Healthy (38) Adverse event disutility (30,33) TB (38) Hospitalization (30) Death Standard * All costs are in 2016 Can $. BCCDC, British Columbia Centre for Disease Control; IGRA, interferon-gamma release assay; INH, isoniazid; LTBI, latent tuberculosis infection; PSA, probabilistic sensitivity analysis; RIF, rifampin; TB, tuberculosis; TST, tuberculin skin test. ([dagger]) Sampled as a percent decrement compared to healthy QALY. Table 4. Results in various TB incidence settings of implementing intervention strategies for screening and treatment of latent TB infection in immigrants * Intervention % Identified for Cost/1,000 postarrival persons,$ followup Low TB incidence countries Base case 0.82 9,681 SEQ/RIF 4.02 60,996 SEQ/INH 4.02 67,309 IGRA/RIF 6.43 80,107 IGRA/INH 6.43 91,056 TST/RIF 22.99 120,910 TST/INH 22.99 162,233 Moderate TB incidence countries Base case 2.88 58,301 SEQ/RIF 11.99 121,950 IGRA/RIF 14.52 129,036 SEQ/INH 11.99 142,739 IGRA/INH 14.52 154,804 TST/RIF 38.96 206,145 TST/INH 38.96 277,998 High TB incidence countries Base case 2.79 122,928 SEQ/RIF 19.13 194,289 IGRA/RIF 23.60 199,878 SEQ/INH 19.13 231,835 TST/RIF 44.24 247,488 IGRA/INH 23.60 263,572 TST/INH 44.24 348,686 Very high TB incidence countries Base case 3.87 184,357 SEQ/RIF 27.45 263,628 IGRA/RIF 33.86 268,840 TST/RIF 49.82 318,025 SEQ/INH 27.45 318,435 IGRA/INH 33.86 337,716 TST/INH 49.82 415,877 Intervention No. No. TB % Reduction QALYs/1,000 cases/1,000 in TB persons persons incidence Low TB incidence countries Base case 13,761.03 0.41 NC SEQ/RIF 13,761.30 0.26 36.87 SEQ/INH 13,761.08 0.28 32.00 IGRA/RIF 13,761.22 0.22 46.16 IGRA/INH 13,761.07 0.25 39.07 TST/RIF 13,760.65 0.24 40.08 TST/INH 13,760.59 0.27 34.12 Moderate TB incidence countries Base case 13,735.03 2.47 NC SEQ/RIF 13,736.36 1.57 36.52 IGRA/RIF 13,736.66 1.33 46.36 SEQ/INH 13,735.71 1.72 30.55 IGRA/INH 13,736.69 1.50 39.47 TST/RIF 13,736.84 1.46 40.77 TST/INH 13,735.98 1.61 34.88 High TB incidence countries Base case 13,702.56 5.39 NC SEQ/RIF 13,704.93 3.44 36.06 IGRA/RIF 13,705.48 2.91 45.99 SEQ/INH 13,704.38 3.73 30.73 TST/RIF 13,704.35 3.28 39.21 IGRA/INH 13,704.93 3.22 40.18 TST/INH 13,704.15 3.54 34.36 Very high TB incidence countries Base case 13,666.32 8.12 NC SEQ/RIF 13,670.25 5.18 36.23 IGRA/RIF 13,671.50 4.41 45.61 TST/RIF 13,670.32 5.62 30.76 SEQ/INH 13,671.23 4.86 40.16 IGRA/INH 13,671.02 4.97 38.82 TST/INH 13,669.91 5.33 34.34 Intervention Cost per QALY gained gained, $ ([dagger]) Low TB incidence countries Base case NC SEQ/RIF 191,889 SEQ/INH 1,289,335 ([double dagger]) IGRA/RIF 373,773 ([double dagger]) IGRA/INH 2,315,425 ([double dagger]) TST/RIF Dominated TST/INH Dominated Moderate TB incidence countries Base case NC SEQ/RIF 47,561 IGRA/RIF 43,343 SEQ/INH 122,821 ([double dagger]) IGRA/INH 58,154 ([double dagger]) TST/RIF 81,548 ([double dagger]) TST/INH 230,641 ([double dagger]) High TB incidence countries Base case NC SEQ/RIF 29,997 IGRA/RIF 26,350 SEQ/INH 59,655 ([double dagger]) TST/RIF 69,421 ([double dagger]) IGRA/INH 59,154 ([double dagger]) TST/INH 141,336 ([double dagger]) Very high TB incidence countries Base case NC SEQ/RIF 20,165 IGRA/RIF 16,291 TST/RIF 33,403 ([double dagger]) SEQ/INH 27,296 ([double dagger]) IGRA/INH 32,657 ([double dagger]) TST/INH 64,494 ([double dagger]) * Very high incidence, [greater than or equal to] 200 cases per 100,000; high incidence: [greater than or equal to] 100 and <200 cases/100,000; moderate incidence, [greater than or equal to] 30 and <100 cases/100,000; low incidence: <30 cases/100,000. IGRA, interferon-gamma release assay; INH, isoniazid; NC, not calculable; QALY, quality-adjusted life year; RIF, rifampin; SEQ, sequential screening; TB, tuberculosis; TST, tuberculin skin test. ([dagger]) * The cost per QALY gained is calculated in comparison to the base case. Dominated indicates that an intervention strategy has higher costs and worse outcomes compared to the base case. Costs are in CAD. ([double dagger]) This intervention strategy is strictly dominated by another intervention strategy. It is more expensive and has worse outcomes.
|Printer friendly Cite/link Email Feedback|
|Author:||Campbell, Jonathon R.; Johnston, James C.; Cook, Victoria J.; Sadatsafavi, Mohsen; Elwood, R. Kevin;|
|Publication:||Emerging Infectious Diseases|
|Date:||Apr 1, 2019|
|Previous Article:||Lobomycosis in Soldiers, Colombia.|
|Next Article:||Spatial Dynamics of Chikungunya Virus, Venezuela, 2014.|